With the start of Asco just around the corner a review of EP Vantage’s cancer coverage from the last six months reveals that a number of tumour types including liver and pancreatic could see some critical data emerge this year.

Meanwhile data on mechanisms like Parp inhibition and CAR-T therapies are also keenly awaited, for clues as to their real potential.

The articles gathered here highlight recent breakthroughs and setbacks and flag the approaching data points.

The report includes a look at:

Ovarian cancer - the field readies itself for phase III readouts

Pancreatic cancer – this time it’s (getting) personal

Parp inhibitors – set to come of age in 2016

CAR-T – how do you solve a problem like relapse?

报告下载：

2016ASCO抗癌药物临床研发进展